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Abstract Our aim was to evaluate the psychometric
properties of the generic quality of life (QoL) scale Child
Health and Illness Proﬁle-Child Edition (CHIP-CE) by
means of a combined analysis of atomoxetine clinical trials
in children and adolescents with attention-deﬁcit/hyper-
activity disorder (ADHD). Individual patient-level data
from ﬁve clinical trials were included in the combined
analysis. Psychometric properties of the CHIP-CE were
explored in terms of internal consistency and structure.
Patients (n = 794) aged between 6 and 15 years (mean
9.7) with mean baseline ADHD Rating Scale of
41.8 ± 8.04 were included. On average, 0.7 (SD 2.23)
items were missing for the whole CHIP-CE. The internal
consistency of the CHIP-CE assessed by Cronbach’s alpha
was good for all sub-domains at baseline and at endpoint.
Considerable ceiling effects were only observed for the
‘‘restricted activity’’ sub-domain. No considerable ﬂoor
effects were seen. The factor analysis supported the
12-factor solution for the sub-domains, but not the 5-factor
solution for the domains. Our analyses were based on a
large sample of non-US patients which allowed the mea-
surement of clear changes in QoL over time. The results
support that the CHIP-CE scale is psychometrically robust
over time in terms of internal consistency and structure.
Keywords Attention-deﬁcit disorder with hyperactivity 
Quality of life  Psychometrics  Factor analysis
Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is a dis-
order characterized by hyperactivity, impulsivity, and
inattention that affects between 3 and 7% of school-age
Trial registration: This is a combined analysis of ﬁve already
published clinical trials.
Preliminary results of this analysis have been presented at the EPA
meeting 2009.
The following publication is based on the same data base but focuses
on the clinical-relevant treatment differences and does not contain the
psychometrical evaluation of the scale: see citation, Escobar et al.
(2010).
A. Schacht (&)
Lilly Deutschland, Global Statistical Sciences,
Werner-Reimers-Str. 2-4, 61350 Bad Homburg, Germany
e-mail: schacht_alexander@lilly.com
R. Escobar
Neuroscience Products, Medical Science,
Lilly Research Laboratories, Sannomiya Plaza Bldg. 7-1-5,
Isogamidori, Chuo-ku, Kobe 651-0086, Japan
e-mail: escobar_rodrigo@lilly.com
T. Wagner
Trilogy Writing & Consulting GmbH,
Falkensteiner Str. 77, 60322 Frankfurt, Germany
P. M. Wehmeier
Vitos Hospital for Psychiatry and Psychotherapy,
Weilstr. 10, 35789 Weilmu ¨nster, Germany
P. M. Wehmeier
Department of Child and Adolescent Psychiatry, Central
Institute of Mental Health, University of Heidelberg, J5,
68159 Mannheim, Germany
123
ADHD Atten Def Hyp Disord (2011) 3:335–349
DOI 10.1007/s12402-011-0066-ychildren (APA 2000). A worldwide pooled prevalence of
5.29% has been reported (Polanczyk et al. 2007). Impair-
ment of ADHD affects cognitive and psychosocial func-
tioning (Barkley 2002; Biederman and Faraone 2005;
Nijmeijer et al. 2008; Escobar et al. 2008) as well as the
quality of life (QoL) in patients and their families (John-
ston and Mash 2001; Sawyer et al. 2002; Klassen et al.
2004; Matza et al. 2004; Escobar et al. 2005; Riley et al.
2006b).
Treatment options for ADHD include psychostimulants,
especially in combination with behavioral therapy (MTA
study) (Jensen et al. 2001) or atomoxetine, which is a non-
stimulant treatment option for ADHD (Cheng et al. 2007).
In most of the studies evaluating the efﬁcacy of these
medications, questionnaires such as the ADHD Rating
Scale (ADHD-RS) (DuPaul et al. 1998a; Faries et al. 2001)
or the clinical global impression (CGI) (Guy 1976;N I M H
1985) have been used as outcome measures for the core
symptoms of ADHD.
Health-related QoL has received increasing attention
both from clinicians and from investigators in children and
adolescents with ADHD (Harpin 2005; Hakkart-van Roijen
et al. 2007; Yang et al. 2007; Bastiaens 2008). Health-
related QoL is a multidimensional concept that reﬂects the
subjective physical, social, and psychological aspects of
health and is distinct from symptoms of the disorder and
objective functional outcomes (Wallander et al. 2001). It
strongly depends on the subjectively perceived impact of
the disorder (and of the respective treatment) on the level
of physical, psychological, and social functioning (Leidy
et al. 1999; Revicki et al. 2000). Some psychometric
instruments are available to assess the health-related QoL,
including the Child Health and Illness Proﬁle, Child Edi-
tion (CHIP-CE) (Riley et al. 2001; Riley et al. 2006b) and
the Child Health Questionnaire (CHQ) (Landgraf et al.
1996). These questionnaires are generic scales that assess
QoL aspects that go beyond the core symptoms of the
disorder and reﬂect various dimensions of QoL. CHIP-CE
has child-, adolescent- and parent-rated versions, allowing
the assessment of the patient’s QoL both from the parent’s
and from the patient’s perspective. The possibility to assess
QoL from different perspectives is a promising character-
istic of this instrument for assessing QoL in children and
adolescents (Schmidt et al. 2001).
A number of studies have shown improvement in health-
related QoL in children and adolescents treated with ato-
moxetine (Michelson et al. 2001; Buitelaar et al. 2004;
Perwien et al. 2004; Matza et al. 2006; Brown et al. 2006;
Perwien et al. 2006; Prasad et al. 2007; Wehmeier et al.
2007, 2008). These studies have used the CHQ, the CHIP-
CE, or other QoL instruments.
Up to now, the psychometric properties of the CHIP-CE
were mostly studied in non-ADHD populations using
cross-sectional data only. Only Riley et al. (2006b) discuss
some psychometric properties of this generic scale in an
ADHD population. They found that internal consistency
reliability was good-to-excellent (Cronbach’s a[0.70) for
all CHIP-CE domains and sub-domains and that almost no
ceiling and ﬂoor effects were observed. A factor analysis of
the sub-domains yielded a 12-factor solution. The domain-
level factor analysis identiﬁed six factors, the four domains
of Satisfaction, Comfort, Resilience and Risk avoidance
and in addition the two sub-domains of the Achievement
domain. Moderate to high correlations between the CHIP-
CE scales and measures of ADHD and family factors were
found. The HRQoL of children in this sample was con-
siderably lower than that of community youth. However,
this analysis has some limitations. First, the patients were
not required to have been diagnosed formally with ADHD
but only the clinical judgment of the investigator if the
patient has hyperactive/inattentive/impulsive symptoms/
problems and had not been formally diagnosed with ADHD
or a hyperactive/inattentive/impulsive syndrome in the past
was required for inclusion into the study. Another analysis
of the study data showed that 11.5% of patients did not
fulﬁll strict ADHD criteria (Do ¨pfner et al. 2006). In addi-
tion, only cross-sectional data were analyzed making any
statements about score sensitivity for changes over time
impossible.
The objectives of the present combined analysis were to
evaluate the psychometric properties of the CHIP-CE at
baseline and over time and to assess the correlation
between parameters related to QoL and those related to
ADHD core symptoms using the individual patient data of
ﬁve clinical trials studying atomoxetine in children and
adolescents with ADHD.
Methods
Study design and procedures
Individual patient-level data from ﬁve clinical trials (four
European and one Canadian, all of which were studies of
atomoxetine using the CHIP-CE) with similar inclusion
and exclusion criteria and similar duration (8–12 weeks’
follow-up) were included in the combined analysis. More
details about the trials are reported elsewhere (Escobar
et al. 2010). Thus, all data from clinical trials studying
atomoxetine and using the CHIP-CE in the Lilly data base
were included. The total number of patients included in the
combined analysis was 794. Three of these studies were
randomized, double-blind trials comparing atomoxetine
with placebo: Study 1 (n = 99) (Svanborg et al. 2009),
Study 2 (n = 149) (Escobar et al. 2007; Montoya et al.
2007), and Study 3 (n = 139) (Curatolo et al. 2007). The
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123fourth study was a randomized, open-label study of ato-
moxetine versus standard of care (Study 4, n = 201)
(Prasad et al. 2007), and the last one was an open-label
atomoxetine study (Study 5, n = 206) (Dickson et al.
2007), where all patients received atomoxetine.
All patients met the DSM-IV diagnostic criteria for
ADHD and had a symptom severity of at least 1.5 stan-
dard deviations (SD) above norm values for the ADHD-
RS (ADHD subscale of the SNAP in Study 3). The
diagnosis was conﬁrmed using the Kiddie-Schedule for
Affective Disorders and Schizophrenia for School-Aged
Children-Present and Lifetime Version (K-SADS-PL) in
all studies except in Study 5. In Studies 2 and 3, basal
CGI-S scores for ADHD were at least 4 or higher. The
double-blind treatment period was between 8 and
12 weeks in the placebo-controlled studies (8 weeks for
Study 3, 10 weeks for Study 1, and 12 weeks for Study
2). Studies 2 and 4 included only medication-naı ¨ve
patients. Study 3, which was carried out in Italy, did not
explicitly require medication-naı ¨ve patients, but at the
time of recruitment, there were no ADHD drugs available
in that country.
The primary scale on which this combined analysis was
based is the Child Health and Illness Proﬁle-Child Edition-
Parent Form (CHIP-CE-Parent Form) (Riley et al. 2001), a
76-item generic health-related quality of life (HR-QoL)
questionnaire, covering a total of ﬁve domains (Satisfac-
tion, Comfort, Risk avoidance, Resilience, and Achieve-
ment) and twelve sub-domains (satisfaction with health
(SH), satisfaction with self (SS), physical comfort (PC),
emotional comfort (EC), restricted activity (RA), individ-
ual risk avoidance (IRA), threats to achievement (TA),
family involvement (FI), physical activity (PA), social
problem solving (SPS), academic performance (AP), and
peer relations (PR)) that were developed in non-ADHD
samples. The CHIP-CE scores are standardized to t-scores,
i.e., to a mean (±SD) of 50 (±10), based on the norm
values, which were derived from a sample of 1,049 school
children from the United States, with higher scores indi-
cating better health. Riley et al. (2004a) found that its
domains (Satisfaction, Comfort, Risk Avoidance, Resil-
ience, and Achievement) measure structurally distinct,
interrelated aspects of health. Furthermore, they summa-
rized that the domain reliability was high with an internal
consistency between 0.79 and 0.88 and a retest reliability
between 0.71 and 0.85 as measured by the intra-class
correlation ICC.
Efﬁcacy on core ADHD symptoms was assessed using
the Attention Deﬁcit/Hyperactivity Disorder Rating Scale-
IV, Parent Version (ADHD-RS), which evaluates all 18
symptoms of ADHD according to the DSM-IV diagnostic
criteria (Guy 1976; DuPaul et al. 1998b). Improvement is
indicated by a decrease in the score. The ADHD-RS
comprises a total score, a hyperactive/impulsive sub-score,
and an inattentive sub-score.
Statistical analysis
The demographic data were analyzed using descriptive
statistics. The number of missing items per evaluation was
computed and also analyzed descriptively as a continuous
variable. The proportion of evaluations without missing
items was presented for the CHIP-CE as a whole and for
the domains and sub-domains. All visits and all ﬁve studies
were pooled for this analysis. Inclusion of patients
receiving active treatment and placebo in the analysis over
time will increase the range of the changes and will thus
lead to a wider basis for the evaluation. The item-total
correlations (Spearman’s and Pearson’s correlation coefﬁ-
cients) were calculated for the total scores as well as for the
domains and sub-domains. Furthermore, the sub-domains
were correlated with the domains and the total score, and
the domains were correlated with the total score. The
items/sub-domains/domains were sorted by their Spear-
man’s correlation coefﬁcient with the respective summary
score. Only the Spearman’s correlation coefﬁcient is
reported here because it is similar to the Pearson’s corre-
lation coefﬁcient for these data. Cronbach’s alpha was
computed for the items that were grouped into a sub-score
and for all subsets of items that can be created by deleting
one item within a sub-domain. The relative frequencies of
ﬂoor effects (lowest possible value observed) and ceiling
effects (highest possible value observed) for the sub-
domains, domains, and total scores are provided. Correla-
tions between domains of the CHIP-CE at baseline and at
endpoint are shown. The same was done for the sub-
domains. A factor analysis based on the sub-domains was
performed additionally in order to explore the relationships
between the sub-domains. Factor analyses using the vari-
max rotation on the 76 items with solutions allowing 5 or
12 factors were performed because the CHIP-CE has 5
domains and 12 sub-domains, as the goal was to replicate
the factor structure seen in the normative sample. Only
loadings[0.30 are presented. All analyses were done using
the SAS statistical program.
Results
Patient population and disposition
A total of 794 patients were included in the analysis. The
age range was 6–15 years. The mean age was 9.7 years
(SD 2.30 years). Most of the patients were children
(\12 years): 611 (77.0%) and male 658 (82.9%). Mean
ADHD-RS total score at baseline was 41.8 (SD 8.04), the
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123inattentive sub-score was 22.2 (SD 3.83), and the hyper-
active/impulsive sub-score was 19.6 (SD 6.03). At base-
line, mean CGI-S ADHD was 4.8 points (SD 0.89).
Baseline total CHIP-CE mean t score was 28.9 (±11.76)
(standard: 50 ± 10); for details, see Table 1. A more
detailed discussion of the impact of ADHD on QoL as
measured by the CHIP-CE can be found elsewhere
(Escobar et al. 2005, 2010).
Internal psychometric properties of the CHIP-CE
Missing values
The proportion of CHIP-CE evaluations with at least one
missing value was 19.4%. On average, 0.7 (SD 2.23) items
were missing for the whole scale. The proportion of CHIP-
CE evaluations with at least one missing value in one of the
domains ranged between 4.1% (Resilience domain) and
9.5% (Comfort domain). The sub-domain with the lowest
proportion of missing values was the PA sub-domain
(0.7%), whereas the sub-domain TA had the highest
number of missing values (6.2%). On average, 0.2 (or less)
items (SDs 0.19–0.96) were missing for the various
domains and sub-domains.
Item-total correlations
To give a clearer impression of item to total score corre-
lation, not all 76 correlations between the individual items
and the total score are shown here. Instead, the quartiles of
the 76 Spearman’s correlation coefﬁcients are reported. At
baseline, the highest correlation with the total score was
r = 0.581; 25% of the items had a higher correlation than
r = 0.455. The median correlation was r = 0.374; 75% of
the items had a higher correlation than r = 0.245. The
lowest correlation was r = 0.055. Item 45 (‘‘How often did
your child play hard enough to start sweating and breathing
hard?’’) had the lowest correlation (r = 0.055; 95% CI -
0.016 to 0.127) and was the only item where zero was
included in the 95% CI (i.e., where the correlation was not
signiﬁcantly higher than 0). A similar pattern of correla-
tions was found at the end of the double-blind phase for the
placebo-controlled studies. Overall, smaller correlations
were observed when correlating the changes from baseline.
The highest correlation was r = 0.502, the 25% quartile
was r = 0.337, the median was r = 0.274, the 75% quar-
tile was r = 0.211, and the lowest correlation was
r = 0.063.
Item-domain correlations
Within the various CHIP-CE domains, the highest and the
lowest Spearman’s correlations between the individual
items and the respective domain are reported in the fol-
lowing. The highest baseline correlation in the Satisfaction
domain was r = 0.743 and the smallest was r = 0.512.
Correlations in the Comfort domain were between
r = 0.305 and r = 0.602, for the Resilience domain
between r = 0.265 and r = 0.643, and for the Achieve-
ment domain between r = 0.468 and r = 0.624. For
the Risk avoidance domain, correlations ranged from
r = 0.268 (item 76 ‘‘How often did he/she have trouble
paying attention in school?’’) to a maximum of r = 0.747.
However, the second lowest correlation within the Risk
avoidance domain had a correlation of r = 0.501. Such a
large difference between item and domain correlation was
not seen for the other domains, where the single item-
domain correlations were more evenly distributed between
the minimum and maximum values.
Correlations were similar at the end of the double-blind
phase for the placebo-controlled studies. However, the
correlation for item 76 (‘‘How often did he/she have
trouble paying attention in school?’’) was not as distinct
from other item to domain correlations as for the baseline
assessment in the Risk avoidance domain.
Overall, lower correlations were seen for changes from
baseline. Here, correlations were between r = 0.386 and
r = 0.664 for the Satisfaction domain, between r = 0.184
and r = 0.526 for the Comfort domain, between r = 0.215
and r = 0.527 for the Risk avoidance domain, between
r = 0.139 and r = 0.524 for the Resilience domain, and
Table 1 Descriptive analysis (mean and SD) of CHIP-CE total score,
domains, and sub-domains at baseline based on all ﬁve studies
Score Non-missing observations Mean ± SD
Total score 793 28.9 ± 11.76
Satisfaction 788 34.4 ± 14.04
Satisfaction with health 787 40.8 ± 13.5
Satisfaction with self 788 31.5 ± 14.37
Comfort 792 43.7 ± 10.82
Physical comfort 792 51.0 ± 9.92
Emotional comfort 791 38.2 ± 11.78
Restricted activity 760 49.7 ± 10.25
Risk avoidance 791 30.2 ± 14.62
Ind. risk avoidance 792 35.7 ± 15.6
Threats to achievement 790 30.9 ± 13.6
Resilience 792 36.0 ± 12.03
Family involvement 791 40.2 ± 11.68
Physical activity 791 46.4 ± 11.77
Social problem solving 789 35.3 ± 12.97
Achievement 777 30.5 ± 10.4
Academic performance 776 31.0 ± 9.95
Peer relations 790 37.1 ± 13.42
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123between r = 0.329 and r = 0.694 for the Achievement
domain.
Item-sub-domain correlations
Within the CHIP-CE sub-domains, the highest and lowest
Spearman’s correlations between the individual items and
the respective sub-domain were also analyzed. At baseline
(endpoint values are provided in brackets), the highest
correlation for the SH sub-domain was r = 0.682 (0.759)
and the smallest was r = 0.590 (0.601). For the SS sub-
domain, the correlations were between r = 0.703 (0.709)
and r = 0.876 (0.868), for the PC sub-domain between
r = 0.437 (0.314) and r = 0.620 (0.666), for the EC sub-
domain between r = 0.527 (0.528) and r = 0.684
(r = 0.758), for the RA sub-domain between r = 0.556
(0.608) and r = 0.863 (0.869), for the IRA sub-domain
between r = 0.670 (0.626) and r = 0.889 (0.853), for the
FI sub-domain between r = 0.419 (0.432) and r = 0.656
(0.690), for the SPS sub-domain between r = 0.721
(0.655) and r = 0.825 (0.807), for the AP sub-domain
between r = 0.641 (0.615) and r = 0.784 (0.818), and for
the PR sub-domain between r = 0.618 (0.573) and
r = 0.832 (0.858). For the TA sub-domain, the minimal
and maximal correlations were r = 0.286 (item 76) (0.361)
and r = 0.712 (0.678), respectively. However, the item
with the second lowest correlations within this sub-domain
had a correlation of r = 0.563 (0.490), showing that item
76 had a particularly low correlation within this sub-
domain. The items for the PA sub-domain were separated
into two groups based on the correlations. Items 44–46 had
correlations between r = 0.778 (0.730) and r = 0.830
(0.832), whereas the items 31–33 had correlations between
r = 0.323 (0. 345) and r = 0.408 (0.377). A similar pat-
tern, but with generally smaller correlations, was observed
for the changes from baseline.
Table 2 shows the Spearman’s correlation coefﬁcients
between the sub-domains and the domains and between the
domains and the total score.
Internal consistency (Cronbach’s alpha)
Internal consistency of CHIP-CE was assessed using
Cronbach’s alpha. The results are shown in Table 3. The
internal consistency was good for all sub-domains at
baseline and at endpoint. Only the EC and FI sub-domains
fell short of a consistency of 0.7, which can be used as a
helpful cut-off (DeVellis 1991). However, no such cut-off
was previously discussed for changes over time. The
internal consistency for changes from baseline to endpoint
was fair, except for AP, which had better internal consis-
tency for changes over time. The internal consistency of all
sub-domains at baseline and endpoint was robust against
single missing items, as the alpha values did not decrease
by any meaningful degree when one item was deleted. The
TA domain and the AP sub-domains were sensitive to
Table 2 Spearman’s correlation coefﬁcients with 95% CIs between the sub-domains and the domains and between the domains and the total
score at baseline, at endpoint after the placebo-controlled period, and for the change from baseline to that endpoint
Sub-domains At baseline At endpoint For change from baseline to endpoint
Satisfaction with health 0.879 (0.860; 0.897) 0.888 (0.865; 0.912) 0.817 (0.771; 0.862)
Satisfaction with self 0.855 (0.833; 0.876) 0.868 (0.839; 0.897) 0.853 (0.819; 0.888)
Emotional comfort 0.866 (0.848; 0.884) 0.872 (0.846; 0.898) 0.813 (0.770; 0.855)
Physical comfort 0.745 (0.709; 0.780) 0.739 (0.689; 0.788) 0.680 (0.616; 0.744)
Restricted activity 0.575 (0.525; 0.625) 0.509 (0.429; 0.589) 0.491 (0.404; 0.578)
Threats to achievement 0.944 (0.936; 0.953) 0.930 (0.912; 0.948) 0.910 (0.885; 0.935)
Ind. risk avoidance 0.823 (0.798; 0.849) 0.756 (0.708; 0.804) 0.657 (0.587; 0.726)
Social problem solving 0.737 (0.703; 0.772) 0.750 (0.702; 0.797) 0.702 (0.642; 0.762)
Family involvement 0.705 (0.667; 0.742) 0.724 (0.669; 0.778) 0.633 (0.561; 0.705)
Physical activity 0.526 (0.472; 0.580) 0.541 (0.463; 0.618) 0.520 (0.439; 0.601)
Peer relations 0.754 (0.721; 0.787) 0.777 (0.732; 0.821) 0.701 (0.644; 0.758)
Academic performance 0.727 (0.691; 0.764) 0.760 (0.712; 0.809) 0.830 (0.782; 0.877)
Domain
Achievement 0.734 (0.698; 0.770) 0.786 (0.739; 0.832) 0.687 (0.625; 0.749)
Satisfaction 0.723 (0.686; 0.760) 0.785 (0.745; 0.825) 0.651 (0.582; 0.719)
Risk avoidance 0.703 (0.664; 0.742) 0.653 (0.593; 0.713) 0.662 (0.595; 0.729)
Resilience 0.625 (0.579; 0.671) 0.667 (0.606; 0.728) 0.589 (0.518; 0.660)
Comfort 0.589 (0.539; 0.638) 0.513 (0.432; 0.594) 0.599 (0.530; 0.668)
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123certain items in terms of change. Alpha was below 0.4 for
these sub-domains based on the changes from baseline to
endpoint when one item was deleted.
Floor and ceiling effects
Floor and ceiling effects were evaluated using the baseline
visits and all subsequent visits to increase the basis of
information, as these effects should not occur at any time.
The ﬂoor and ceiling effects of the total score were less
than 0.1% at baseline and across all visits. The same holds
for the ﬂoor effects of all domains. The largest ceiling
effect of the domains was seen for the Satisfaction domain
when all visits were pooled (1.3%). Floor effects of the
sub-domains were mostly below 1%. The AP sub-domain
had the largest ﬂoor effect based on baseline values (3.5%).
Ceiling effects varied across the different sub-domains and
were generally lower if only the baseline visit was taken
into account. At baseline, the ceiling effect was below 1%
for the sub-domains SH, TA, AP, and PR. The ceiling
effect increased to values between 1 and 2% if all visits
were taken into account. The sub-domains SS (baseline),
EC (baseline and for all visits), IRA (baseline), FI (baseline
and for all visits), and SPS (baseline and for all visits) had
values between 1 and 5%. Higher ceiling effects were
discovered for the sub-domains SS (all visits: 6.9%), PC
(baseline: 5.9%, all visits: 9.1%), RA (baseline: 54.6%, all
visits: 58.7%), IRA (all visits: 8.2%), and PA (baseline:
7.3%, all visits: 8.9%).
Factor analyses based on individual items
Factor analyses with solutions allowing 5 or 12 factors were
performed because the CHIP-CE has 5 domains and 12 sub-
domains (see Tables 4, 5 for the loadings). The factor anal-
ysis was based on baseline data only. The ﬁrst factor of the
12-factor solution mainly consists of items from the sub-
domains IRA and TA, which together form the Risk avoid-
ancedomain.Highloadingsofthesecondfactorcamealmost
exclusively from the EC domain. The third factor had high
loadings not only from all four SS items, but also from two
items from the SH sub-domain (item 1: ‘‘How often does
your child have a lot of fun?’’ and item 4: ‘‘How often does
yourchildfeelhappy?’’).The5itemsoftheSPSsub-domain
Table 3 Cronbach’s alpha
(standardized) for the sub-
domains and the lowest alpha
that was reached by deleting an
item in that sub-domain with
95% CIs
Sub-domains At baseline At endpoint For change from
baseline to endpoint
Cronbach’s alpha (standardized) with 95% CIs
Satisfaction with health 0.771 (0.747; 0.796) 0.801 (0.770; 0.832) 0.611 (0.550; 0.672)
Satisfaction with self 0.815 (0.793; 0.836) 0.831 (0.803; 0.859) 0.676 (0.622; 0.730)
Physical comfort 0.726 (0.697; 0.755) 0.689 (0.642; 0.736) 0.567 (0.501; 0.633)
Emotional comfort 0.822 (0.803; 0.841) 0.835 (0.810; 0.861) 0.760 (0.723; 0.797)
Restricted activity 0.799 (0.776; 0.823) 0.865 (0.842; 0.888) 0.746 (0.703; 0.789)
Ind. risk avoidance 0.816 (0.795; 0.838) 0.740 (0.697; 0.784) 0.597 (0.530; 0.665)
Threats to achievement 0.821 (0.802; 0.840) 0.789 (0.756; 0.821) 0.679 (0.628; 0.729)
Family involvement 0.705 (0.674; 0.736) 0.713 (0.669; 0.757) 0.560 (0.492; 0.627)
Physical activity 0.729 (0.698; 0.760) 0.699 (0.649; 0.750) 0.589 (0.521; 0.656)
Social problem solving 0.828 (0.809; 0.847) 0.803 (0.771; 0.835) 0.663 (0.609; 0.718)
Academic performance 0.775 (0.747; 0.803) 0.831 (0.796; 0.867) 0.738 (0.682; 0.794)
Peer relations 0.822 (0.803; 0.842) 0.804 (0.772; 0.836) 0.450 (0.362; 0.539)
Lowest Cronbach’s alpha (standardized) with 95% CIs by deleting an item in the respective domain
Satisfaction with health 0.724 (0.694; 0.755) 0.760 (0.722; 0.798) 0.544 (0.472; 0.617)
Satisfaction with self 0.712 (0.677; 0.747) 0.754 (0.710; 0.797) 0.553 (0.474; 0.632)
Physical comfort 0.688 (0.655; 0.721) 0.627 (0.570; 0.684) 0.500 (0.423; 0.576)
Emotional comfort 0.793 (0.771; 0.815) 0.808 (0.778; 0.837) 0.723 (0.680; 0.766)
Restricted activity 0.705 (0.669; 0.742) 0.784 (0.745; 0.823) 0.612 (0.543; 0.681)
Ind. risk avoidance 0.692 (0.654; 0.729) 0.568 (0.492; 0.645) 0.388 (0.280; 0.496)
Threats to achievement 0.792 (0.770; 0.814) 0.757 (0.720; 0.795) 0.639 (0.582; 0.696)
Family involvement 0.642 (0.604; 0.681) 0.653 (0.599; 0.707) 0.481 (0.400; 0.562)
Physical activity 0.675 (0.637; 0.713) 0.639 (0.579; 0.700) 0.505 (0.423; 0.587)
Social problem solving 0.771 (0.745; 0.797) 0.742 (0.699; 0.786) 0.566 (0.493; 0.639)
Academic performance 0.685 (0.645; 0.726) 0.764 (0.712; 0.816) 0.639 (0.560; 0.718)
Peer relations 0.764 (0.736; 0.791) 0.719 (0.672; 0.766) 0.327 (0.215; 0.439)
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123composed the fourth factor. These items did not load onto
otherfactorsandnootheritem loadedtoanyrelevantdegree
ontofactor four.The3outof6PAitems,which were related
to running and walking, loaded high onto the ﬁfth factor,
togetherwithsmallerloadingfromitem34(‘‘Feeltoosickto
play at home?’’), item 10 (‘‘My child is physically ﬁt’’), and
item 11 (‘‘My child is well coordinated’’). All AP items
loaded high onto the sixth factor, together with smaller
loadingsfromtwoTAitems(item74:‘‘Howoftendidhe/she
getalongwithhis/herteacher?’’anditem76:‘‘Howoftendid
he/she have trouble paying attention in school?’’). The AP
itemsloadednearlyexclusivelyontothisfactor.Onlytheﬁve
PR items loaded onto factor seven, and only two of these
items had smaller loadings onto the ﬁrst factor. No loadings
onto any relevant degree for the PR items were observed in
terms of any other factor. The four items composing the RA
sub-domain made up almost exclusively the factor eight.
Again, only one of these items had a smaller loading onto
another factor. Factor nine contained all nine PC items,
which loaded only onto this factor (except foritem 5). All FI
items made up factor ten. Loadings of these items onto other
factors were minor. The group of PA items that relate to
games and sports loaded high onto factor eleven. Factor
twelvereceivedloadingsfromfourofthesixitemsoftheSH
sub-domain, three of which did not load onto other factors.
Also, an EC item (item 21: ‘‘How often did your child have
trouble falling asleep?’’) and a PC item (item 5: ‘‘How often
is your child sick?’’) loaded onto this factor.
The result of a factor analysis based on 5 factors is
shown in Table 4. All but one item of the Risk avoidance
items (item 76) loaded onto the ﬁrst factor displayed in the
ﬁrst column. Additionally, two items from the Comfort
domain, four items from the Achievement domain, and
four items from the Resilience domain loaded onto this
factor. These loadings were generally smaller than the
loadings from the Risk avoidance items. All of the Comfort
domain items, which are related to RA, loaded onto the
second factor as displayed in the second column. Further-
more, seven of the nine Comfort domain items, which
belong to the PC sub-domain, had loading onto the second
factor. The other two PC items did not have loadings of
more than 0.3 onto any factor. Only one of the other
comfort items (i.e., those related to EC) had a small loading
for this factor. Those three of six PA items from the
Resilience domain that were related to running and walking
loaded high onto this factor too. Furthermore, three SH
items had medium loadings onto this factor. All the SS
items loaded onto the third factor together with four SH
items. This factor also received high loadings from the four
Achievement domain items of which the PR sub-domain
consists. Smaller loadings were also seen for Resilience
items, which were mostly related to PA (i.e., games and
sports). The fourth factor consisted mainly of items related
to EC and received almost no loadings from the other two
Comfort sub-domains. Smaller loadings also came from a
few Satisfaction items. The ﬁfth and last factor received
loadings mainly from the FI sub-domain, which belongs to
the Resilience domain, and the AP sub-domain, which
belongs to the Achievement domain.
Correlations between domains of the CHIP-CE
Table 6 shows the correlations between the domains at
baseline and at endpoint. Most correlations were higher at
endpoint than at baseline. The pattern of correlations was
similar in both analyses. The Risk avoidance domain had the
lowest correlations compared with other domains, both at
baseline and at endpoint. However, this was not the case for
changesfrombaselinetoendpoint.Thehighestcorrelationfor
change was seen between the Achievement and Risk avoid-
ance domains (r = 0.462), followed bythe domains Comfort
versus Satisfaction (r = 0.360), Resilience versus Satisfac-
tion(r = 0.323),RiskavoidanceversusComfort(r = 0.309),
Achievement versus Satisfaction (r = 0.290), Achievement
versus Resilience (r = 0.270), Resilience versus Risk avoid-
ance (r = 0.261), Achievement versus Comfort (r = 0.221),
Resilience versus Comfort (r = 0.212), and Risk avoidance
versus Satisfaction (r = 0.198).
Correlations between sub-domains of the CHIP-CE
Table 7 shows the correlations between the sub-domains at
baseline and at endpoint. Six sub-domains (SH, SS, EC, TA,
SPS,andPR)correlatewiththreeormoreothersub-domains
with r[0.3, both at baseline and at endpoint. Three further
sub-domains correlate withthreeormoreothersub-domains
with r[0.3, at baseline (PC, RA, and IRA). The highest
correlationsfoundwerer = 0.603atbaselineandr = 0.559
at endpoint. Three sub-domains appear to be correlated with
other sub-domains to a lower degree. At baseline, all corre-
lations were less than 0.3 for FI. At endpoint, only the cor-
relations with SS (r = 0.412) and with SPS (r = 0.319)
werehigherthan0.3.PAiscorrelated(r[0.3)withSHonly
at baseline (r = 0.368) and at endpoint (r = 0.393). AP is
not correlated with any other sub-domain at baseline and
only with TA at endpoint (r = 0.356). For correlations
between changes from baseline to endpoint, only four cor-
relations were stronger than 0.3: SS versus SH (r = 0.441),
AP versus TA (r = 0.380), TA versus IRA (r = 0.336), and
PC versus SH (r = 0.307).
Factor analyses based on original sub-domains
of CHIP-CE
A factor analysis based on the sub-domains is another
approach to exploring relationships between sub-domains
Psychometric properties of the CHIP-CE 341
123Table 4 Factor analysis with 12 factors (varimax rotation) for the CHIP-CE (only loadings[0.30 are presented)
Items Sub-domains 1234567891 0 1 1 1 2
1 SH 0.61
2S H 0.64
3S H 0.60
4 SH 0.31 0.61
5P C 0.32 0.39 0.41
6 SS 0.71
7 SS 0.78
8 SS 0.70
9 SS 0.58
10 SH 0.48 0.32
11 SH 0.33 0.32
12 SH 0.36
13 PC 0.34
14 PC 0.50
15 PC 0.55
16 PC 0.68
17 PC 0.41
18 PC 0.51
19 PC 0.53
20 PC 0.49
21 EC 0.37 0.35
22 EC 0.62
23 EC 0.33 0.49
24 EC 0.55
25 EC 0.66
26 EC 0.33 0.65
27 EC 0.68
28 EC 0.72
29 EC 0.63
30 RA 0.59
31 PA 0.77
32 PA 0.81
33 PA 0.72
34 RA 0.40 0.62
35 RA 0.67
36 RA 0.70
37 FI 0.31 0.39
38 FI 0.31
39 FI 0.46
40 FI 0.7
41 FI 0.34 0.39
42 FI 0.67
43 FI 0.65
44 PA 0.73
45 PA 0.76
46 PA 0.80
47 FI 0.60
48 IRA 0.55
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123(see Table 8). This approach takes all correlations into
account simultaneously. The pattern of correlations
described above is conﬁrmed with this method. The sub-
domains IRA, TA, SPS, and PR load strongly onto the ﬁrst
factor. The second factor consists mainly of the three
Comfort sub-domains. Each of the other three factors (3, 4,
and 5) received high loading from one of the individual
sub-domains mentioned above. The second highest loading
for the third factor after PA is SH. The second highest
loading for the fourth factor after FI is SS. TA and AP load
onto factor 5.
Correlations between CHIP-CE and ADHD-RS
At baseline, correlations between the total score, the
domains, and the sub-domains of the CHIP-CE versus
ADHD-RS total score were low (\0.4) (e.g., CHIP-CE
total score: r =- 0.345) except for the Risk avoidance
domain (r =- 0.517) and its sub-domains (individual
risk avoidance r =- 0.481, threats to achievement r =
-0.463). More detailed information about these correla-
tions between CHIP-CE and ADHD-RS as well as the
treatment effect of atomoxetine in terms of these scales can
be found elsewhere (Escobar et al. 2010). A more detailed
proﬁle over time of the CHIP-CE was evaluated in the
SUNBEAM study by Prasad et al. (2007).
Discussion
The objective of this combined analysis was to evaluate the
psychometric properties of the CHIP-CE in a sample of
children and adolescents with ADHD from clinical studies.
The analyses were based on the data from ﬁve clinical trials
Table 4 continued
Items Sub-domains 1234567891 0 1 1 1 2
49 IRA 0.77
50 IRA 0.75
51 IRA 0.56
52 PR 0.66
53 PR 0.75
54 PR 0.35 0.65
55 PR 0.68
56 TA 0.68
57 TA 0.58
58 TA 0.68
59 TA 0.69
60 PR 0.35 0.53
61 TA 0.54
62 TA 0.49
63 TA 0.54
64 SPS 0.70
65 SPS 0.71
66 SPS 0.7
67 SPS 0.66
68 SPS 0.75
69 AP 0.82
70 AP 0.72
71 AP 0.66
72 AP 0.72
73 TA 0.54
74 TA 0.38 0.32
75 AP 0.36 0.44
76 TA 0.49
SH satisfaction with health, SS satisfaction with self, PC physical comfort, EC emotional comfort, RA restricted activity, IRA individual risk
avoidance, TA threats to achievement, FI family involvement, PA physical activity, SPS social problem solving, AP academic performance, PR
peer relations
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123Table 5 Factor analysis with ﬁve factors (varimax rotation) for the CHIP-CE (only loadings[0.30 are presented)
Items Sub-domains Domains 1 2 3 4 5
1 SH Satisfaction 0.54 0.31
2 SH Satisfaction 0.41 0.31
3 SH Satisfaction
4 SH Satisfaction 0.52 0.44
5 PC Comfort 0.59
6 SS Satisfaction 0.50 0.33 0.34
7 SS Satisfaction 0.51 0.40
8 SS Satisfaction 0.50
9 SS Satisfaction 0.48 0.37
10 SH Satisfaction 0.46 0.41
11 SH Satisfaction 0.32
12 SH Satisfaction 0.55
13 PC Comfort
14 PC Comfort 0.42
15 PC Comfort
16 PC Comfort 0.44
17 PC Comfort 0.40
18 PC Comfort 0.42
19 PC Comfort 0.40
20 PC Comfort 0.40 0.32
21 EC Comfort 0.45
22 EC Comfort 0.69
23 EC Comfort 0.31 0.52
24 EC Comfort 0.52
25 EC Comfort 0.59
26 EC Comfort 0.31 0.63
27 EC Comfort 0.60
28 EC Comfort 0.65
29 EC Comfort 0.34 0.51
30 RA Comfort 0.51
31 PA Resilience 0.55
32 PA Resilience 0.58
33 PA Resilience 0.60
34 RA Comfort 0.64
35 RA Comfort 0.67
36 RA Comfort 0.68
37 FI Resilience 0.46
38 FI Resilience 0.41
39 FI Resilience
40 FI Resilience 0.50
41 FI Resilience 0.32 0.40
42 FI Resilience 0.50
43 FI Resilience 0.50
44 PA Resilience 0.47
45 PA Resilience 0.37
46 PA Resilience 0.42
47 FI Resilience 0.33
48 IRA Risk avoidance 0.52
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123of atomoxetine. The descriptive CHIP-CE baseline data of
these studies conﬁrmed the impairment in terms of QoL in
this clinical trial population with moderate core symptoms
severity. The psychometric evaluation of the CHIP-CE
showed a low number of missing items, conﬁrming that the
questionnaire comprising 76 items is relatively easy to
apply (Riley et al. 2004a, 2006b). The correlations between
the items and the total score were stable over time as the
item-total correlations showed a similar pattern at baseline
and after the double-blind phase for the placebo-controlled
studies. Smaller correlations were observed between
changes from baseline values. The similarity of the corre-
lations at baseline and at endpoint indicates that the total
score was sensitive to the same items at both points in time,
a result that could not be shown by the cross-sectional
analysis by Riley et al. (2004a, 2006b). The same holds
true for the various domains. Interestingly, the item-total
correlations varied widely for the Risk avoidance domain.
Such a gap was not seen for any of the other domains. The
item with the weakest correlation to the domain score
Table 6 Spearman’s correlation coefﬁcients between domains of the CHIP-CE at baseline (above diagonal) and at endpoint (below diagonal)
Satisfaction Comfort Risk avoidance Resilience Achievement
Satisfaction 1 0.420 0.226 0.448 0.426
Comfort 0.366 1 0.326 0.195 0.258
Risk avoidance 0.245 0.281 1 0.305 0.452
Resilience 0.528 0.168 0.285 1 0.322
Achievement 0.523 0.175 0.500 0.444 1
Table 5 continued
Items Sub-domains Domains 1 2 3 4 5
49 IRA Risk avoidance 0.75
50 IRA Risk avoidance 0.72
51 IRA Risk avoidance 0.55
52 PR Achievement 0.53
53 PR Achievement 0.64
54 PR Achievement 0.47 0.49
55 PR Achievement 0.35 0.52
56 TA Risk avoidance 0.70
57 TA Risk avoidance 0.54
58 TA Risk avoidance 0.66
59 TA Risk avoidance 0.65
60 PR Achievement 0.43
61 TA Risk avoidance 0.50
62 TA Risk avoidance 0.51
63 TA Risk avoidance 0.57
64 SPS Resilience 0.34 0.42
65 SPS Resilience 0.46 0.39
66 SPS Resilience 0.50
67 SPS Resilience 0.31 0.38 0.34
68 SPS Resilience 0.45 0.46
69 AP Achievement 0.58
70 AP Achievement 0.52
71 AP Achievement 0.48
72 AP Achievement 0.44
73 TA Risk avoidance 0.62
74 TA Risk avoidance 0.45 0.32
75 AP Achievement 0.40 0.33
76 TA Risk avoidance
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123‘‘trouble paying attention at school’’ is closely related to
the core symptoms of ADHD. Therefore, the low correla-
tion with the Risk avoidance domain suggests that in the
ADHD population, this item belongs to a different
dimension than other items in this domain. Correlation
patterns were similar at the end of the double-blind phase
for the placebo-controlled studies. However, the weak
correlation for item ‘‘trouble paying attention at school’’
was not as distinct as for the baseline assessment in the
Risk avoidance domain. Weaker correlations were seen for
the changes from baseline analyses.
The assessment of the item-sub-domain correlations
yielded a similar pattern for the TA sub-domain, which is
part of the Risk avoidance domain, for baseline and end-
point. The items for the PA sub-domain could be separated
into two groups based on the correlations with three items
that had a much higher correlation with the sub-domain
than the other items. Items 44 (‘‘How often did your child
play active games or sports?’’), 45 (‘‘How often did your
child play hard enough to start sweating and breathing
hard?’’), and 46 (‘‘How often did your child run hard when
he/she played or did sports?’’) had much higher correla-
tions compared with the items 31 (‘‘How often did your
child have trouble walking one block?’’), 32 (‘‘How often
did your child have trouble walking up one ﬂight of
stairs?’’), and 33 (‘‘How often did your child have trouble
running?’’). A similar pattern, but with overall weaker
correlations, was observed for the changes from baseline.
Correlations between sub-domains and domains and
between domains and the total score were similar at
baseline and endpoint. The correlations for change from
baseline were usually slightly smaller. The RA and the PA
sub-domains had lower correlations with their domains
than most of the other domains at baseline, at endpoint, and
Table 7 Spearman’s correlation coefﬁcients ([0.3) between sub-domains of the CHIP-CE at baseline (above diagonal) and at endpoint (below
diagonal)
SH SS PC EC RA IRA TA FI PA SPS AP PR
SH 1 0.520 0.358 0.338 0.319 0.368 0.394
SS 0.559 1 0.325 0.329 0.379
PC 1 0.389 0.405
EC 0.319 0.406 1 0.325 0.345 0.380
RA 0.363 0.402 1
IRA 1 0.603 0.343 0.312
TA 0.365 0.483 1 0.421 0.362
FI 0.412 1
PA 0.393 1
SPS 0.307 0.367 0.319 1 0.372
AP 0.356 1
PR 0.482 0.421 0.326 0.346 0.399 1
Table 8 Factor analysis loadings ([0.3) based on sub-domains of the CHIP-CE at baseline (varimax rotation)
Sub-domain Factor 1 Factor 2 Factor 3 Factor 4 Factor 5
Satisfaction with health 0.42 0.56 0.38
Satisfaction with self 0.40 0.62
Physical comfort 0.81
Emotional comfort 0.34 0.74
Restricted activity 0.59 0.48
Ind. risk avoidance 0.69
Threats to achievement 0.71 0.38
Family involvement 0.84
Physical activity 0.84
Social problem solving 0.66 0.33
Academic performance 0.84
Peer relations 0.76 0.33
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123also for the change from baseline. The same was found to
be true for the Comfort domain regarding the correlation of
the domain with the total score. The Achievement domain,
the Satisfaction domain, and the Risk avoidance domain
seem to be especially important components of the CHIP-
CE scale in children and adolescents with ADHD, based on
their strong correlation with the total score. The low cor-
relation of the other two domains, Resilience and Comfort,
might be caused by the fact that these contain sub-domains
that are not affected by ADHD at baseline (PC, RA, and
PA). This was not only observed in the present population
of patients with ADHD, but also in a cross-sectional
sample from the United States on which Riley et al. (2007)
based their analysis.
The internal consistency as measured by Cronbach’s
alpha for all sub-domains was good at baseline and at
endpoint, which conﬁrms the ﬁndings from an observa-
tional study with ADHD patients (Riley et al. 2006b)a s
well as the results based on a community sample (Riley
et al. 2004a). The internal consistency for changes from
baseline to endpoint as measured by Cronbach’s alpha
was moderate, except for AP where it was low. Therefore,
the CHIP-CE is generally useful to track changes in QoL
over time. The internal consistency of domains and sub-
domains was robust against single missing items, except
for changes in the TA sub-domain and the AP sub-
domain. Results from those sub-domains should only be
used if all items are available. Considerable ceiling effects
were only observed for the RA domain, which is not
surprising in a sample selected based on a psychiatric and
not a physical condition. A similar proﬁle of ﬂoor and
ceiling effects was seen in an observational study in
ADHD patients (Riley et al. 2006b). The RA domain had
also most ceiling effect (6.3%) in a community sample
(Riley et al. 2004a). The factor analysis allowing for 12
factors showed that the sub-domains generally load onto
different factors; especially the sub-domains that are
impaired in ADHD patients can be distinguished. How-
ever, this is not the case for the 5-factor solution based on
the number of CHIP-CE domains, where the items from
sub-domains that do not belong to the same domain often
load together on one factor. It is therefore advisable to
use the sub-domains rather than the domains of the CHIP-
CE when evaluating ADHD patients. This is supported by
the factor analysis based on the sub-domains and the
correlation analysis of the sub-domains, which showed
that those sub-domains that belong to the same domain do
not necessarily have a high correlation. Riley et al.
(2006a) also found a 12-factor solution in a cross-sec-
tional naturalistic ADHD sample. This is an important
difference to the results of CHIP-CE domains previously
reported in a community sample (Riley et al. 2004a, b;
Rajmil et al. 2004). The correlation between the domains
over time was stable in our analysis. The same holds true
for the sub-domains. A cluster of between-sub-domain
correlations was observed for nine sub-domains, which
showed correlations of [0.3 with three or more sub-
domains at baseline and/or at endpoint. In contrast, the
three sub-domains FI, PA, and AP appeared to be less
correlated with the others.
Possible limitations of this evaluation are the different
designs of the studies on which this combined analysis was
based, including different patient populations with respect
to pre-treatment and comorbidities. Therefore, these results
may not be directly transferable to epidemiological sam-
ples. Furthermore, it is difﬁcult to assess how the proxy
evaluation by the parents may have inﬂuenced the rela-
tionship between QoL and the core symptoms. The inﬂu-
ence of the QoL of the parents or the parents’ diseases
(such as ADHD) could not be assessed because these data
were not obtained.
Conclusions
The strength of this analysis is the large sample of patient
data from outside of the United States. This large sample
size together with the longitudinal assessment of the
questionnaire makes this analysis unique. Previous evalu-
ations of the CHIP-CE used only cross-sectional samples
and thus could not assess its performance in measuring
changes over time. Our ﬁndings suggest that the applica-
tion of the CHIP-CE provides useful and psychometrical
robust insights into the QoL in terms of internal consis-
tency and structure—especially when evaluating the sub-
domains. Based on this combined analysis, the CHIP-CE
can also be recommended to track changes in QoL over
time.
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